
News|Articles|December 1, 2012
Pipeline Preview
Recent FDA action (through November 2012) related to, H5N1 adjuvanted influenza vaccine, Pasireotide, Digoxin immune fab, Etirinotecan pegol, OBI-1, beclomethasone 17, 21-dipropionate, Regorafenib, Trastuzumab emtansine, A4250, Sildenafil
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare
2
Myqorzo is now available for rare heart condition at a $108,400 annual price
3
When it comes to quality measures, fewer is viewed as better, says Ben Shirley of PQA | Part 2
4
Could GLP-1s help with cognitive symptoms, pychosis of schizophrenia?
5























